Elafibranor Patent Expiration

Elafibranor was first introduced by Ipsen Biopharmaceuticals Inc in its drug Iqirvo on Jun 10, 2024.

Elafibranor Patents

Given below is the list of patents protecting Elafibranor, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Iqirvo	US11185519	Methods of treatment of cholestatic diseases	Mar 30, 2037	Ipsen
Iqirvo	US11331292	Methods of treatment of cholestatic diseases	Mar 30, 2037	Ipsen
Iqirvo	US11850223	Methods of treatment of cholestatic diseases	Mar 30, 2037	Ipsen
Iqirvo	US11857523	Methods of treatment of cholestatic diseases	Mar 30, 2037	Ipsen
Iqirvo	US7632870	Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof	Sep 09, 2024 (Expired)	Ipsen
Iqirvo	US7943661	Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof	Sep 09, 2024 (Expired)	Ipsen

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List